Our Barcelona facility accommodates full drug research and development - including prototyping, developing and upscaling of production processes, the development and validation of analytical methods and stability studies of the prototypes - as well as production and packaging of registration batches.
Production activities involve the manufacture of tablets and capsules, as well as packaging in blisters, sachets and bottles and further release to the market. With its more than 460 employees, the site handles over 85 different products (molecules/strengths). Regulatory approvals have been obtained from the Spanish Drug Agency (EMA), U.S. FDA, Korean FDA, ANVISA Brazil and the governmental health department of Catalonia among others. Synthon Hispania holds the ISO14001 and OHSAS18001 certifications.
In 2016, Synthon Hispania was again named a Best Workplace® according to the Spanish Great Place to Work Institute®. In 2020, Synthon Hispania was named among the 109 companies that have been certified as Top Employers Spain.go to Synthon Hispania website
Total manufacturing capacity